 |
2 Products |  |
0 Diseases | | 2 Products |
|
12 Trials |  |
291 News |  |
| «1234 |
- | Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Trial completion date, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Dec 12, 2018
P1/2, N=41, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2021 --> Jun 2020
- || suvemcitug (APX003) / Simcere, Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial, Combination therapy: A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. (clinicaltrials.gov) - Dec 4, 2018
P1b, N=48, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- | sotigalimab (APX005M) / Apexigen
New P2 trial, Combination therapy, Metastases: APX005M and Doxorubicin in Advanced Sarcoma (clinicaltrials.gov) - Oct 25, 2018
P2, N=27, Not yet recruiting, Sponsor: Columbia University
- | Neo Vax (NEO-PV-01) / BioNTech
Enrollment open, Metastases: A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma (clinicaltrials.gov) - Oct 12, 2018
P1b, N=40, Recruiting, Sponsor: Neon Therapeutics, Inc.
Trial completion date: Jun 2021 --> Jun 2020 Not yet recruiting --> Recruiting
- | sotigalimab (APX005M) / Pyxis Oncology
Enrollment closed: Study of the CD40 Agonistic Monoclonal Antibody APX005M (clinicaltrials.gov) - Aug 7, 2018
P1, N=43, Active, not recruiting, Sponsor: Apexigen, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Neo Vax (NEO-PV-01) / BioNTech
New P1 trial, Metastases: A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma (clinicaltrials.gov) - Jul 24, 2018
P1b, N=40, Not yet recruiting, Sponsor: Neon Therapeutics, Inc.
- ||| sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Combination therapy, Metastases: APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (clinicaltrials.gov) - Jun 19, 2018
P1, N=120, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | sotigalimab (APX005M) / Pyxis Oncology
Trial primary completion date: Study of the CD40 Agonistic Monoclonal Antibody APX005M (clinicaltrials.gov) - Apr 27, 2018
P1, N=50, Recruiting, Sponsor: Apexigen, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Dec 2018
- Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Trial completion date, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 3, 2018
P1/2, N=41, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Jun 2020 --> Jun 2021
- sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
Trial completion date, Trial primary completion date: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Mar 1, 2018
P1, N=27, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Trial completion date: Jun 2020 --> Jun 2021 Trial primary completion date: Sep 2017 --> Jun 2018 | Trial completion date: Sep 2017 --> Sep 2018
- sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
Trial initiation date, Trial primary completion date: A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Mar 1, 2018
P1, N=36, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Trial primary completion date: Sep 2017 --> Jun 2018 | Trial completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Nov 2017 --> Nov 2018 | Initiation date: Sep 2017 --> Oct 2017
- sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Trial initiation date: Phase I Study of APX005M in Pediatric CNS Tumors (clinicaltrials.gov) - Feb 6, 2018
P1, N=45, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Nov 2017 --> Nov 2018 | Initiation date: Sep 2017 --> Oct 2017 Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018
- | Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 12, 2018
P1/2, N=41, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jan 2018 --> Feb 2018 Active, not recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment closed, Enrollment change, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jan 9, 2018
P1/2, N=7, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | N=41 --> 7
- | sotigalimab (PYX-107) / Pyxis Oncology
New P1 trial: Phase I Study of APX005M in Pediatric CNS Tumors (clinicaltrials.gov) - Jan 4, 2018
P1, N=45, Active, not recruiting, Sponsor: Pediatric Brain Tumor Consortium
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment status, PD(L)-1 Biomarker, Metastases: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - Dec 12, 2017
P1, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=41 --> 7 Enrolling by invitation --> Recruiting
- | sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Combination therapy: APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers (clinicaltrials.gov) - Oct 18, 2017
P2, N=16, Recruiting, Sponsor: University of California, San Francisco
Enrolling by invitation --> Recruiting Not yet recruiting --> Recruiting
- sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
Enrollment open, Trial initiation date: A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 7, 2017
P1, N=36, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Sep 2017
- sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
Trial primary completion date: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Aug 18, 2017
P1, N=27, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Sep 2017 Trial primary completion date: Jun 2017 --> Sep 2017
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment change, PD(L)-1 Biomarker, Metastases: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - Aug 10, 2017
P1, N=60, Enrolling by invitation, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2017 --> Sep 2017 N=40 --> 60
- |||| sotigalimab (PYX-107) / Pyxis Oncology, Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment open, Metastases: PRINCE: Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 3, 2017
P1b/2, N=105, Recruiting, Sponsor: Parker Institute for Cancer Immunotherapy
N=40 --> 60 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jun 8, 2017
P1/2, N=41, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | sotigalimab (PYX-107) / Pyxis Oncology
New P2 trial, Combination therapy: APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers (clinicaltrials.gov) - May 24, 2017
P2, N=16, Not yet recruiting, Sponsor: University of California, San Francisco
- |||| sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, Combination therapy, Metastases: CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab (clinicaltrials.gov) - May 20, 2017
P1/2, N=99, Recruiting, Sponsor: Apexigen, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- sotigalimab (APX005M) / Pyxis Oncology
Enrollment change, Trial primary completion date: Study of the CD40 Agonistic Monoclonal Antibody APX005M (clinicaltrials.gov) - May 19, 2017
P1, N=50, Recruiting, Sponsor: Apexigen, Inc.
Not yet recruiting --> Recruiting N=32 --> 50 | Trial primary completion date: Apr 2017 --> Dec 2017
- ||||| sotigalimab (PYX-107) / Pyxis Oncology
New P1/2 trial, Combination therapy, Metastases: CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab (clinicaltrials.gov) - Apr 20, 2017
P1/2, N=99, Not yet recruiting, Sponsor: Apexigen, Inc.
- | Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 3, 2017
P1/2, N=41, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
N=32 --> 50 | Trial primary completion date: Apr 2017 --> Dec 2017 Initiation date: Oct 2016 --> May 2017 | Trial primary completion date: Oct 2019 --> May 2020
- | sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
New P1 trial: A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 17, 2017
P1, N=36, Not yet recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
- sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
Trial primary completion date: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Sep 8, 2016
P1, N=27, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
Initiation date: Oct 2016 --> May 2017 | Trial primary completion date: Oct 2019 --> May 2020 Trial primary completion date: Aug 2016 --> Jun 2017
- | Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 20, 2016
P1/2, N=41, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2016 --> Jun 2017 Initiation date: Jun 2016 --> Oct 2016 | Trial primary completion date: Jun 2019 --> Oct 2019
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment status, PD(L)-1 Biomarker, Metastases: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - Jun 9, 2016
P1, N=40, Enrolling by invitation, Sponsor: M.D. Anderson Cancer Center
Initiation date: Jun 2016 --> Oct 2016 | Trial primary completion date: Jun 2019 --> Oct 2019 Recruiting --> Enrolling by invitation
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Enrollment open, PD(L)-1 Biomarker, Metastases: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - May 13, 2016
P1, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - May 11, 2016
P1, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2021 --> Jul 2021
- | Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
New P1/2 trial, Combination therapy, Metastases: APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Mar 11, 2016
P1/2, N=41, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | sevacizumab (APX003) / Simcere, Apexigen, Mabwell (Shanghai) Biosci
New P1 trial: Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Nov 24, 2015
P1, N=27, Recruiting, Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Keytruda (pembrolizumab) / Merck (MSD), sotigalimab (PYX-107) / Pyxis Oncology
New P1 trial, PD(L)-1 Biomarker, Metastases: Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov) - Nov 9, 2015
P1, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Enrollment open, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2015
P1, N=36, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Initiation date: Mar 2016 --> Jul 2016 | Trial primary completion date: Mar 2021 --> Jul 2021 Not yet recruiting --> Recruiting
- suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
Enrollment change, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2015
P1, N=36, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting N=22 --> 36
- sotigalimab (APX005M) / Pyxis Oncology
New P1 trial: Study of the CD40 Agonistic Monoclonal Antibody APX005M (clinicaltrials.gov) - Jun 26, 2015
P1, N=32, Recruiting, Sponsor: Apexigen, Inc.
- | suvemcitug (APX003) / Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial, Metastases: A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 26, 2015
P1, N=22, Not yet recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
- suvemcitug (APX003) / Simcere, Mabwell (Shanghai) Biosci, Pyxis Oncology
Trial primary completion date, Metastases: A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 19, 2015
P1, N=31, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
N=22 --> 36 Trial primary completion date: Jul 2014 --> Nov 2015
- | suvemcitug (APX003) / Simcere, Mabwell (Shanghai) Biosci, Pyxis Oncology
New P1 trial, Metastases: A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - May 2, 2013
P1, N=31, Recruiting, Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.